tiprankstipranks
Trending News
More News >
Sprint Bioscience AB (SE:SPRINT)
:SPRINT

Sprint Bioscience AB (SPRINT) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Sprint Bioscience AB

(Frankfurt:SPRINT)

Rating:39Underperform
Price Target:
Sprint Bioscience's overall stock score is low, primarily due to financial challenges such as negative profitability and cash flows, bearish technical indicators, and unattractive valuation metrics. The lack of debt is a positive, but the company needs to improve revenue stability and cost efficiency to enhance its financial health.

Sprint Bioscience AB (SPRINT) vs. iShares MSCI Sweden ETF (EWD)

Sprint Bioscience AB Business Overview & Revenue Model

Company DescriptionSprint Bioscience AB (SPRINT) is a biotechnology company based in Sweden, specializing in the early-stage development of oncology therapeutics. The company focuses on the discovery and development of innovative small-molecule drug candidates targeting cancer metabolism and tumor immune evasion. Their leading programs are aimed at addressing unmet medical needs in cancer treatment by advancing proprietary projects through preclinical phases, with the ultimate goal of out-licensing them to pharmaceutical partners for further development and commercialization.
How the Company Makes MoneySprint Bioscience generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical companies. By advancing its drug candidates to a preclinical stage, the company positions itself to enter partnerships where it grants rights to its drug candidates in exchange for upfront payments, milestone payments, and royalties on future sales. These partnerships allow Sprint Bioscience to leverage the resources and expertise of established pharma companies to bring its innovations to market. Additionally, the company may receive government grants or research funding to support its development projects, although these are not its primary revenue streams.

Sprint Bioscience AB Financial Statement Overview

Summary
Sprint Bioscience faces typical financial challenges in the biotechnology sector, with volatile revenues and negative profitability metrics. Despite maintaining a debt-free position, negative cash flows and profitability are significant concerns that need addressing.
Income Statement
40
Negative
Sprint Bioscience has demonstrated inconsistent revenue growth, with a notable jump from 2022 to 2023, but profitability remains a concern due to persistent negative EBIT and net income margins. The company struggles with generating consistent gross profits, indicating cost management issues.
Balance Sheet
55
Neutral
The balance sheet reflects significant reliance on equity financing with no debt, which is positive for financial stability. However, the return on equity remains negative due to continuing net losses. Despite a small equity base, the absence of debt limits financial risk.
Cash Flow
35
Negative
Cash flows are volatile, with a shift from positive to negative operating cash flow in recent years. Free cash flow has been consistently negative, reflecting challenges in generating sufficient cash from operations to cover capital expenditures.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
65.64M50.48M83.00K35.11M16.89M
Gross Profit
37.30M41.79M-60.91M24.68M6.43M
EBIT
-19.67M-845.00K-60.91M-25.47M-37.67M
EBITDA
-17.32M-2.08M-60.00M-24.49M-38.05M
Net Income Common Stockholders
-18.28M-438.00K-60.17M-25.35M-46.23M
Balance SheetCash, Cash Equivalents and Short-Term Investments
25.06M49.93M29.49M70.64M27.07M
Total Assets
42.05M62.38M37.42M79.14M33.40M
Total Debt
0.000.000.000.0010.00M
Net Debt
-25.06M-49.93M-29.49M-70.64M-17.07M
Total Liabilities
32.78M34.60M9.23M8.68M24.25M
Stockholders Equity
9.27M27.77M28.19M70.45M9.14M
Cash FlowFree Cash Flow
-24.65M20.42M-59.05M-42.82M-32.22M
Operating Cash Flow
-23.36M22.87M-59.05M-40.12M-32.22M
Investing Cash Flow
-1.30M-2.45M0.00-2.71M0.00
Financing Cash Flow
-225.00K24.00K17.90M86.39M50.92M

Sprint Bioscience AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.42
Price Trends
50DMA
0.58
Negative
100DMA
0.99
Negative
200DMA
1.26
Negative
Market Momentum
MACD
-0.06
Negative
RSI
34.36
Neutral
STOCH
28.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Negative. The current price of 0.42 is below the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.58, and below the 200-day MA of 1.26, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 34.36 is Neutral, neither overbought nor oversold. The STOCH value of 28.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPRINT.

Sprint Bioscience AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
52
Neutral
kr48.51M-47.01%-94.12%-25.83%
46
Neutral
€60.48M-66.45%-36.71%72.81%
42
Neutral
kr52.11M-222.24%58.36%
39
Underperform
€44.11M-147.64%30.02%-3985.71%
38
Underperform
€73.82M-105.78%58.72%70.69%
34
Underperform
kr29.19M-105.54%63.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SPRINT
Sprint Bioscience AB
0.42
-0.96
-69.62%
SE:COMBI
CombiGene AB
2.45
-0.83
-25.30%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
22.75
-21.57
-48.67%
SE:MODTX
Modus Therapeutics Holding AB
1.45
0.41
38.76%
SE:SPAGO
Spago Nanomedical AB
0.21
-0.13
-38.73%
SE:STABL
Stayble Therapeutics AB
0.45
0.19
71.59%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.